|
|
5-day change | 1st Jan Change | ||
|
50.23 USD |
+0.52% | +5.05% | -10.94% | |
Published on 06/11/2025 at 10:54
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Bristol-Myers Squibb’s Sotyktu to Treat Psoriatic Arthritis Meets Primary Goal |
10:54am |
MT |
|
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis |
08:37am |
CI |
|
Bristol Myers’ Sotyktu Shows Superiority Over Placebo in Phase 3 Psoriatic Arthritis Trial |
07:03am |
RE |
|
Bristol-Myers Squibb Unit Enters License for Prostate Cancer Drug Candidate Rights |
04:17am |
MT |
|
Philochem Announces Licensing Of Oncoacp3, To Rayzebio, A Bristol-Myers Squibb Company, For A Potential Value Of Up To $1.35Bn Plus Royalties |
06:03pm |
RE |
|
Health Rounds: Older breast cancer patients using estrogen cream live longer, study finds |
Jun. 04 |
RE |
|
Sector Update: Health Care Stocks End Higher Late Afternoon |
Jun. 02 |
MT |
|
Sector Update: Health Care Stocks Retreat in Afternoon Trading |
Jun. 02 |
MT |
|
HSBC Raises Bristol-Myers Squibb’s Price Target to $50 From $47 |
Jun. 02 |
MT |
|
Top Midday Stories: Steel Stocks Soar After Trump Doubles Steel Tariffs; Bristol Myers Squibb, BioNTech to Collaborate on Tumor Therapy |
Jun. 02 |
MT |
|
Sector Update: Health Care Stocks Advance Pre-Bell Monday |
Jun. 02 |
MT |
|
BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion |
Jun. 02 |
DJ |
|
BioNTech, Bristol Myers Squibb to Co-Develop Bispecific Cancer Treatment |
Jun. 02 |
MT |
|
Biontech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-Generation Bispecific Antibody Candidate Bnt327 Broadly for Multiple Solid Tumor Types |
Jun. 02 |
CI |
|
Regeneron shares slide on mixed trial data for smoker’s lung drug |
May. 30 |
RE |
|
Meitheal Launches Generic Form of Bristol-Myers Squibb’s Abraxane in US |
May. 29 |
MT |
|
Bristol-Myers Squibb Company Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 03:30 PM |
May. 28 |
|
|
Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo |
May. 28 |
MT |
|
Debt, Diplomacy, and a Silicon Savior |
May. 28 |
 |
|
Bristol Myers Squibb Gets EC Approval for Subcutaneous Formulation of Opdivo |
May. 28 |
MT |
|
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? Across Multiple Solid Tumor Indications |
May. 28 |
CI |
|
Bristol Myers: EU green light for Opdivo subcutaneous injection |
May. 28 |
CF |
|
Bristol Myers Gets European Approval for Subcutaneous Opdivo |
May. 28 |
DJ |
|
Berenberg Adjusts Price Target on Bristol-Myers Squibb to $55 From $60, Maintains Hold Rating |
May. 28 |
MT |
|
Analyst recommendations: Applovin, Broadcom, Chewy, Fair Isaac, Fortinet… |
May. 28 |
|
BMY: Dynamic Chart
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l’hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
More about the company
Buy
Average target price
57.10USD
Spread / Average Target
+14.26%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
